Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Oct 27.
Published in final edited form as: Science. 2026 Apr 30;392(6797):536–542. doi: 10.1126/science.aef0610

Scanning nitrogen in sp3-rich scaffolds enabled by carbonyl-to-nitrogen atom swap

Zining Zhang 1, Zhehan Liang 1, Rong Ye 1, Guangbin Dong 1
PMCID: PMC13698604  NIHMSID: NIHMS2215340  PMID: 42060755

Abstract

Medicinal chemistry campaigns routinely require access to series of saturated nitrogen heterocycle (SNH)-based analogues that place nitrogen at different positions to probe structure–activity relationships. However, systematic preparation of N-positional variants remains synthetically burdensome. Here we report a strategy for nitrogen scanning in sp3-rich scaffolds enabled by exchange of a carbonyl group with an amine moiety, formally achieving a CO-to-N atom swap. Because ketone positional isomers can be readily obtained via carbonyl transposition or C–H oxidation from a common carbocyclic precursor, the CO-to-N atom swap greatly streamlines the preparation of SNH positional analogues and obviates the need for multiple de novo syntheses. The CO-to-N reaction exhibits exceptional functional group compatibility and generality, making it well suited for late-stage modification of complex bioactive molecules and for isotopic labeling.


Saturated nitrogen heterocycles (SNHs) are prevalent in small-molecule drugs, and the position of the nitrogen atom typically has a strong influence on the potency and physicochemical properties, known as the “necessary nitrogen atom” effect (1-3) (Fig. 1A). For example, repositioning the nitrogen atom in a Bruton's tyrosine kinase (BTK) inhibitor leads to a remarkable 21-fold increase in potency (1, 2). In a niraparib analog, altering the location of the nitrogen within the piperidine ring determines whether the compound is effective or inactive as a poly-ADP-ribosylation (PARylation) inhibitor (3). Similarly, in the case of fentanyl, a slight positional change of the nitrogen results in an 88-fold difference in opiate receptor inhibiting activity (4). Clearly, during lead optimization and SAR studies, it is essential to evaluate analogues in which the nitrogen atom occupies different positions—a process commonly referred to as nitrogen scanning (3). To date, access to each N-positional analog primarily relies on de novo synthesis, necessitating distinct starting materials and the redesign of synthetic routes. The emerging skeletal editing methods offer elegant approaches to introduce N-positional analogs through modifying aromatic rings (Fig. 1B) (5-7). In comparison to the π-rich or aromatic systems (8-14), replacing atoms in sp3-rich scaffolds requires breaking and re-forming multiple strong and inert σ bonds (15-19). Hence, scanning nitrogen in saturated systems remains a largely unmet challenge.

Fig. 1. Scanning nitrogen in sp3-rich scaffolds.

Fig. 1.

(A) Examples of how the position of the nitrogen atom influences the performance of bioactive compounds. (B) Established strategies for nitrogen scanning in aromatic systems. (C) Nitrogen scanning in sp3-rich systems enabled by coupling carbonyl transportation with the CO-to-N atom swap. (D) Nitrogen scanning through merging the CO-to-N atom swap with late-stage C–H oxidation.

We postulated that the key to enable rapid access to multiple N-positional analogues of SNHs is to identify a common precursor that can either undergo facile functional group (FG) translocation or introduce FGs at multiple sites. In this context, the carbonyl group represents an ideal precursor to amines for several reasons. In 2021, our laboratory developed a regioselective carbonyl 1,2-transposition method based on palladium/norbornene (Pd/NBE) cooperative catalysis (20). More recently, Bhawal and Morandi (21), Dixon (22), and Wu (23) independently developed complementary approaches to migrate carbonyl groups in various cyclic scaffolds. In parallel, the emerging late-stage C–H oxidation technologies pioneered by White (24-26) and Costas (27) enable ketone installation at multiple positions of cycloalkanes. Thus, if a carbonyl group can be efficiently transformed into a nitrogen atom, it would then become possible to access multiple SNH-based positional isomers from a common carbocycle precursor, serving as a general solution for nitrogen scanning in sp3-rich scaffolds (Fig. 1C and 1D). Moreover, ketones are readily obtained from the corresponding alcohols or alkenes, which are FGs frequently encountered in complex pharmaceuticals and natural products, suggesting that the CO-to-N atom-swap transformation would also be valuable for late-stage functionalization of bioactive molecules and access to novel analogs.

Reaction development.

Despite the conceptual promise, there are few if any straightforward methods for replacing a carbonyl group with a nitrogen atom via late-stage modification (28). The challenge is substantial, as it requires efficiently breaking two unstrained C(sp3)─acyl bonds and successively forming two C(sp3)─N bonds, without perturbing various FGs present in complex molecules. Given that pharmaceutically relevant compounds typically contain nucleophilic (hydrogen bond acceptor) and/or electrophilic (hydrogen bond donor) motifs, single-electron (i.e., radical)-mediated bond deconstructions (29-31), generally exhibiting orthogonal FG compatibility to traditional two-electron processes, are expected to offer exceptional chemoselectivity. Utilizing aromatization as a driving force, we previously demonstrated efficient C–C bond cleavages of unstrained ketones through a prearomatic intermediate (PAI) intermediate (19, 32, 33,). In particular, tethering an aryl halide moiety to a N′-alkyl-hydrazonamide (NAHA) reagent allows sequential homolytic cleavage of both C─C bonds of ketones (19). Here, to achieve the desired CO-to-N atom swap, it is essential to identify a suitable reagent capable of promoting two successive radical-mediated C─N bond formations with the two alkyl radical termini derived from the ketone. However, unlike radical reactions involving heavy elements, Sh2 reactions with a nitrogen center are much rarer (Fig. 2A) (34). In addition, although radical azidation is a well-established process, the intramolecular radical addition to azides is not efficient (especially when forming 6-membered rings) and often complicated by side reactions (35). Hence, designing an effective nitrogen-based double radical acceptor is crucial.

Fig. 2. Developing the carbonyl-to-nitrogen atom swap strategy.

Fig. 2.

(A) Design of the N-centered double radical acceptor. (B) Reaction design of the CO-to-N atom swap. (C) Condition optimization using PAI-1a as a model substrate. (D) Development of one-pot transformations. For detailed reaction conditions, see the Supplementary Materials. Unless mentioned otherwise, all reactions were run with PAI-1a (0.1 mmol), 2a (0.05 mmol) or 3a (0.1 mmol). The yield was determined by 1H NMR with 1,1,2,2-tetrachloroethane as the internal standard. Py, 2-pyridyl. AIBN, azobisisobutyronitrile. HAT, hydrogen atom transfer. SET, single electron transfer. BSA, bis(trimethylsilyl)acetamide. n.d., not detected.

We hypothesized that sulfonyl diazenes could serve as effective double radical acceptors (Fig. 2A). In this proposal, the sulfonyl radical-triggered C─C bond cleavage of the PAI, formed in situ via condensation of the NAHA reagent with a cyclic ketone, would yield an alkyl radical intermediate (19, 36, 37) that attacks the diazene moiety to forge a C─N bond (Fig. 2B). Subsequent elimination of the sulfonyl radical, a well-established radical leaving group (38), could then furnish an alkyl diazene that can then be intercepted intramolecularly by a distal alkyl radical (39), generated through the aryl halide-triggered second C─C bond activation. A final hydrogen-atom-transfer (HAT) step would then quench the resulting N-centered radical, completing the conversion of the cyclic ketone to the SNH. To test this hypothesis, PAI-1a derived from simple cyclohexanone was employed as the model substrate (Fig. 2C). NAHA-G2 containing an aryl bromide moiety was used as the key reagent, as it exhibits better stability and better accessibility than the corresponding iodide-based analog used previously (19). Indeed, the employment of p-tosylphenyldiazene (TsN2Ph) as the radical acceptor successfully delivered the corresponding azo-substituted ring-opening product (2a) in 89% yield. Gratifyingly, azo 2a was subsequently converted to the desired piperidine product (3a) in decent yield during the second C─C bond activation event, i.e., treatment with 1.6 equivalents of (n-Bu)3SnH and 30 mol% AIBN in CH3CN at 100 °C for 24 hours. Free piperidine (4a) can be accessed in nearly quantitively yield from 3a after a mild reduction with zinc. Besides TsN2Ph, other nitrogen-based radical acceptors were also investigated. While the use of the TsN3 can afford the azidation product, the subsequent intramolecular radical addition to the azide moiety exhibits poor efficiency, possibly owing to the difficulty of forming the sp-hybridized N-radical intermediate (35). A range of N-Ts imines showed low reactivities in both the imine transfer and the radical annulation processes, though the more electron-deficient imines promoted the cyclization, likely due to the polar effect(40, 41). Unfortunately, the sulfoximines and sulfilimines were inactive in the first radical addition event. After examining various aryl-substituted p-tosyldiazenes, the simple phenyl substituted compound, i.e., TsN2Ph, remained optimal. Comparable results were obtained with the tolyl-substituted diazene, whereas the more electron-deficient analogs gave much lower yield.

Control experiments were next conducted to better understand the second C–C activation step. First, both (n-Bu)3SnH and AIBN proved critical for this transformation (entries 2 and 3). Replacing (n-Bu)3SnH with less reactive (TMS)3SiH significantly decreased the yield (entry 4). Other silane-based hydrides with stronger Si─H bonds were ineffective to deliver the desired product (entries 5-7). Regarding to the choice of solvent, benzene performed slightly better than CH3CN, while the use of PhCF3 led to diminished reactivity. On the other hand, acetic acid and carbonate base were found to be detrimental to this reaction, though the exact reason remains unclear (entries 10 and 11). Finally, the annulation process favors more dilute conditions (entry 12), which likely minimize the undesired intermolecular HAT with (n-Bu)3SnH.

The PAI formation and the first activation event can be efficiently run in one step (Fig. 2D). In addition, the second activation and the piperidine deprotection can also be run in one pot to afford the free amine (4) with comparable yield to the two-step sequence, though the protected piperidines (3) remained the preferred isolates during the substrate-scope studies due to their ease of purification and characterization (vide infra). Moreover, one-pot protocols for converting the 4-phenylcyclohexanone to the corresponding protected piperidine (3b) and free piperidine (4b) have been realized with good overall efficiency.

Substrate scope.

The generality and FG compatibility of the CO-to-N atom swap were first examined in the context of synthesizing pharmaceutically relevant SNHs (4b-4o) (Fig. 3). From readily available γ- and β-substituted cyclohexanones, the atom swap reaction offers a pair of piperidine positional isomers (3b and 3c), which, upon reductive cleavage of the N─N bond, delivered two known compounds exhibiting complementary biological activities. While piperidines represent one of the most abundant heterocycles in small-molecule drugs (42), the CO-to-N transformation is not limited to forming six-membered SNHs; seven-membered (azepine 3d) and five-membered (pyrrolidine 3e) rings were also obtained in good yields. Moreover, the reaction tolerates a remarkable range of FGs, including esters (3i, 3n, 3o, 3s and 3ab), phenol (3j), free alcohols (3k and 3t), aryl chlorides and fluorides (3k and 3aa), tertiary and secondary amides (3p and 3x), aryl ketones (3h and 3l), pyrazole(3q), ketal (3v), alkyne (3y), aryl triflate (3z) and 1,1-disubstituted olefin (3ac). In most cases, PhNH-protected piperidine products were isolated (instead of free amines) because they are much less polar and so easier to purify. The substrates with an α substituent (3f, 3ab and 3ac) worked well, and cyclohexanones bearing a C4 quaternary center (1g) were competent too. Apart from forming simple piperidines, this strategy is also effective to form spiro-N-heterocycles (3l and 3m), as well as piperazine (3r) and morpholine (3u). For the substrate that contained two symmetrical ketones (3w), it is possible to activate just one ketone moiety by employing one equivalent of NAHA-G2. Considering the widespread occurrence of SNHs in pharmaceutical applications, the removal of the NHPh group, sometimes coupled with simple downstream transformations, provides rapid access to a suite of known bioactive compounds that exhibit a wide spectrum of bioactivities (4b-4o), including the drugs pirodavir and propiverine. The intention of these examples is not to suggest that this method surpasses their original synthetic routes in terms of preparing any specific target molecule; rather, it serves to underscore the generality and versatility of the CO-to-N strategy in directly preparing a wide range of bioactive compounds from readily accessible ketones.

Fig. 3. Scope of the CO-to-N atom swap strategy.

Fig. 3.

Unless noted otherwise, the yield for the first activation step was determined by 1H NMR with 1,1,2,2-tetrachloroethane as the internal standard. The overall yield was determined by isolation. The yields for the second activation step were calculated based on the overall yield and the yield of the first activation step. Condition A (deprotection): Zn (5.0 equiv.), acetic acid (0.2 M) at room temperature. Condition B (reductive amination): aldehyde (1.2 equiv.), NaB(OAc)3H (2.0 equiv.) in 30% acetic acid aqueous solution at room temperature. Condition C (alkylation): MeI (5.0 equiv.) in MeOH, reflux. *For references of the biological activity data of compounds 4b-4o, see the Supplementary Materials. †The yield of a 1.0 mmol scale reaction is reported.

Synthetic utility.

Access to positional isomers of piperidine-containing bioactive compounds was first explored through integrating carbonyl 1,2-transposition with the CO-to-N atom swap (Fig. 4). From the readily available ketone precursors, the Pd/NBE-catalyzed method (20) delivered the corresponding translocated ketones with complete site-selectivity, and the subsequent CO-to-N atom swap of the resulting ketone isomers conveniently produced two positional isomers of the cyclic amines in a divergent manner. Using this general strategy, pairs of positional isomers based on the paroxetine structure (3ad-A/B), the niraparib structure (3ae-A/B), and analogs of a caspase-like protein inhibitor (43) (3af-A/B) and an opiate receptor inhibitor (4) (3ag-A/B), have been successfully obtained, which would otherwise require separate de novo syntheses. In addition, the Bhawal and Morandi carbonyl transposition approach allows simultaneous generation of distinct isomers of cycloketones (21), providing a highly streamlined route to multiple SNH positional variants from a single precursor. For example, ketone 1ah-A, prepared in two steps from commercially available starting materials, was transformed over three steps into three fully separable positional isomers (3ah-A/B/C) of a monoglyceride lipase inhibitor (44). The carbonyl intermediates (1ah-A/B/C), though separable, were used directly as a mixture in the CO-to-N transformation. In total, only five steps were required to obtain all three analogs, whereas synthesis of a single analog alone via the conventional approach demands five steps (45).

Fig. 4. Nitrogen scanning in sp3-rich scaffolds by merging carbonyl transposition with CO-to-N atom swap.

Fig. 4.

Unless noted otherwise, the yield for the first activation step was determined by 1H NMR with 1,1,2,2-tetrachloroethane as the internal standard. The overall yield was determined by isolation. The yields for the second activation step were calculated by the overall yield and the yield of the first activation step. *The yield was determined using pure ketone starting materials. †The reaction was conducted with a mixture of 1ah-(A/B/C) as the starting material, and the yield of each product was determined based on the actual amount of the ketone in the starting material mixture.

As an alternative strategy for preparing diverse positional variants of SNHs, the CO-to-N atom swap can be merged with established C–H oxidation methods by White (24, 25) and Costas (27), enabling a net “CH2-to-N” transformation (Fig. 5A). Given that the C–H oxidation can occur at more than one site on the cycloalkane substrate or across different rings, this approach complements to the carbonyl transposition for accessing ketone isomers. Five representative pairs of examples are shown, and isomers of the corresponding piperidine products are fully separable. Notably, the pair of quinoline-derived piperidines (3ak-A/B) previously required a 10-step synthesis (46), whereas the present strategy delivers them in only four steps from commercial starting materials.

Fig. 5. Further synthetic utilities of the CO-to-N atom swap strategy.

Fig. 5.

(A) Scanning nitrogen through merging C–H oxidation with CO-to-N atom swap. (B) Late-stage modification of ketone-containing complex bioactive compounds. (C) Isotopic labelling enabled by CO-to-N atom swap. *For details, see Supplementary Materials. The yields of 3ai-A/B, 3aj-A/B, 3ak-A/B, 3al-A/B and 3am-A/B were determined based on the actual amount of the ketone in the mixture after the C–H oxidation step.

To showcase additional utility of the CO-to-N method, late-stage modifications of natural products and known bioactive compounds to prepare unusual analogs were explored (Fig. 5B). To our delight, substrates derived from cholesterol (1an), mifepristone (1ap) and ketone-containing inhibitors (1ao, 1aq and 1ar) all underwent smooth CO-to-N atom swap to afford the corresponding N-heterocycle analogs that would otherwise be challenging to prepare with the conventional approaches. For example, four-step reduction was realized to prepare the azacholesterol (3an) compared to the known six-step procedure (29). Additional FGs, such as oxime ether (3ao), electron-rich tertiary amine and tetrasubstituted olefin (3ap), tertiary alkyl ether (3aq), lactam and trifluoromethyl ether (3ar) were found to be compatible. Moreover, the application of this method can be extended to access isotopically labeled amines by taking advantage of the favorable reactivity of ketones (Fig. 5C). Owing to facile H/D exchange at the α-position of ketones, in situ deuteration of substrate 1b followed by CO-to-N atom swap delivered the tetradeuterated amine product (3b-D) in just two steps, whereas the prior synthesis required 7 steps (47). Alternatively, the use of the 15N-enriched TsN2Ph reagent, conveniently prepared from sodium 15N-nitrite, allowed efficient preparation of the previously unknown 15N-labelled product 3b-15N with nearly complete isotope incorporation, offering an attractive approach for late-stage 15N-labelling (48).

Conclusions.

we have developed an efficient CO-to-N atom-swap strategy that converts ketones into the corresponding cyclic amines. Coupling this transformation with carbonyl 1,2-transposition and C–H oxidation streamlines the preparation of positional isomers of SNH-containing bioactive molecules, enabling rapid nitrogen scanning within sp3-rich scaffolds. Because the CO-to-N conversion proceeds through radical-based deconstruction, the method exhibits exceptional FG tolerance. Given that ketones are abundant native FGs that permit straightforward α- and β-functionalization, this CO-to-N atom-swap strategy also offers a conceptually distinct route to access functionalized SNHs. Altogether, this method further expands the utility of NAHA reagents for late-stage modification of sp3-rich frameworks, showcasing its potential value in medicinal chemistry.

Supplementary Material

Supplementary Materials

Materials and Methods

Supplementary Text

Figs. S1 to S4

Tables S1 to S6

References (49-107)

Acknowledgments:

Dr B. Kim (University of Chicago) is thanked for checking the experimental procedure.

Funding:

The research was supported by NIGMS (R01GM109054) and the university of Chicago. Z.Z. thanks a BMS graduate fellowship.

Footnotes

Competing interests: A provisional patent has been filed on the NAHA reagents and their utilities (Zining Zhang, Guangbin Dong, the University of Chicago).

Data and materials availability: Characterization data and details for the synthesis of all reported compounds are in supplementary materials.

References

  • 1.Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, Woyach JA, Johnson AJ, Byrd JC, Crews CM, Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry 57, 3564–3575 (2018). [DOI] [PubMed] [Google Scholar]
  • 2.Liu S, Da Y, Wang F, Yan R, Shu Y, Lin P, Lin J, Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs. Med. Chem. Res. 29, 802–808 (2020). [Google Scholar]
  • 3.Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, Scarpelli R, Schultz-Fademrecht C, Toniatti C, Rowley M, Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors. J. Med. Chem. 52, 7170–7185 (2009). [DOI] [PubMed] [Google Scholar]
  • 4.Lobbezoo MW, Soudijn W, Van Wijngaarden I, Opiate receptor interaction of compounds derived from or structurally related to fentanyl. J. Med. Chem. 24, 777–782 (1981). [DOI] [PubMed] [Google Scholar]
  • 5.Jurczyk J, Woo J, Kim SF, Dherange BD, Sarpong R, Levin MD, Single-atom logic for heterocycle editing. Nat. Synth. 1, 352–364 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pearson TJ, Shimazumi R, Driscoll JL, Dherange BD, Park D-I, Levin MD, Aromatic nitrogen scanning by ipso-selective nitrene internalization. Science 381, 1474–1479 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wang Z, Xu P, Guo S-M, Daniliuc CG, Studer A, C-to-N atom swapping and skeletal editing in indoles and benzofurans. Nature 642, 92–98 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Luu QH, Li J, A C-to-O atom-swapping reaction sequence enabled by Ni-catalyzed decarbonylation of lactones. Chem. Sci. 13, 1095–1100 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Reisenbauer JC, Green O, Franchino A, Finkelstein P, Morandi B, Late-stage diversification of indole skeletons through nitrogen atom insertion. Science 377, 1104–1109 (2022). [DOI] [PubMed] [Google Scholar]
  • 10.Lu H, Zhang Y, Wang X-H, Zhang R, Xu P-F, Wei H, Carbon–nitrogen transmutation in polycyclic arenol skeletons to access N-heteroarenes. Nat. Commun. 15, 3772 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Paschke A-SK, Brägger Y, Botlik BB, Staudinger E, Green O, Morandi B, Carbon-to-nitrogen atom swap enables direct access to benzimidazoles from drug-like indoles. Nat. Chem. 17, 1750–1756 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Roure B, Alonso M, Lonardi G, Yildiz DB, Buettner CS, dos Santos T, Xu Y, Bossart M, Derdau V, Méndez M, Llaveria J, Ruffoni A, Leonori D, Photochemical permutation of thiazoles, isothiazoles and other azoles. Nature 637, 860–867 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yorimitsu H, Aromatic Metamorphosis: Skeletal Editing of Aromatic Rings. Acc. Chem. Res. 58, 1323–1334 (2025). [DOI] [PubMed] [Google Scholar]
  • 14.Park D-I, Gelato Y, Masterson J, Ke J, Tsymbal A, Levin M, Embracing Triplet Aryl Nitrenes for C-to-N Transmutation of Complex Molecules. ChemRxiv 2026, (2026). doi: 10.26434/chemrxiv-2026-jn9zb. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lyu H, Kevlishvili I, Yu X, Liu P, Dong G, Boron insertion into alkyl ether bonds via zinc/nickel tandem catalysis. Science 372, 175–182 (2021). [DOI] [PubMed] [Google Scholar]
  • 16.Zhong H, Egger DT, Gasser VCM, Finkelstein P, Keim L, Seidel MZ, Trapp N, Morandi B, Skeletal metalation of lactams through a carbonyl-to-nickel-exchange logic. Nat. Commun. 14, 5273 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Amber C, Petitjean TM, Sirvinskaite G, Steele RT, Sprague B, Domack J, Small DW, Sarpong R, Two-Step Constitutional Isomerization of Saturated Cyclic Amines Using Borane Catalysis. JACS Au 5, 851–857 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Steele RT, Fujiu M, Sarpong R, 1,2-Acyl transposition through photochemical skeletal rearrangement of 2,3-dihydrobenzofurans. Science 388, 631–638 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zhang Z, Dong G, Carbonyl-to-sulfur swap enabled by sequential double carbon-carbon bond activation. Science 388, 1436–1440 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wu Z, Xu X, Wang J, Dong G, Carbonyl 1,2-transposition through triflate-mediated α-amination. Science 374, 734–740 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Brägger Y, Green O, Bhawal BN, Morandi B, Late-Stage Molecular Editing Enabled by Ketone Chain-Walking Isomerization. J. Am. Chem. Soc. 145, 19496–19502 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Shennan BDA, Sánchez-Alonso S, Rossini G, Dixon DJ, 1,2-Redox Transpositions of Tertiary Amides. J. Am. Chem. Soc. 145, 21745–21751 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ji K, Liao Y, Deng S, Wu Z, Angle-Strained Cycloalkyne-Mediated Carbonyl 1,2-Transposition. ChemRxiv 2025, (2025). doi: 10.26434/chemrxiv-2025-79gqk. [DOI] [Google Scholar]
  • 24.Chen MS, White MC, Combined Effects on Selectivity in Fe-Catalyzed Methylene Oxidation. Science 327, 566–571 (2010). [DOI] [PubMed] [Google Scholar]
  • 25.Chambers RK, Weaver JD, Kim J, Hoar JL, Krska SW, White MC, A preparative small-molecule mimic of liver CYP450 enzymes in the aliphatic C–H oxidation of carbocyclic N-heterocycles. Proc. Natl. Acad. Sci. U. S. A. 120, e2300315120 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ahn C, Gomez A, Hartmann MA, White MC, Selective methylene oxidation in α,β-unsaturated carbonyl natural products. Nature 648, 607–615 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Milan M, Bietti M, Costas M, Highly Enantioselective Oxidation of Nonactivated Aliphatic C─H Bonds with Hydrogen Peroxide Catalyzed by Manganese Complexes. ACS Cent. Sci. 3, 196–204 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Suginome H, Yamada S, Wang JB, Photoinduced molecular transformations. Part 107. A versatile substitution of a carbonyl group of steroidal ketones by a heteroatom. The synthesis of aza-, oxa-, thia-, selena-, and tellurasteroids. J. Org. Chem. 55, 2170–2176 (1990). [Google Scholar]
  • 29.Smaligo AJ, Swain M, Quintana JC, Tan MF, Kim DA, Kwon O, Hydrodealkenylative C(sp3)–C(sp2) bond fragmentation. Science 364, 681–685 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wen L, Ding J, Duan L, Wang S, An Q, Wang H, Zuo Z, Multiplicative enhancement of stereoenrichment by a single catalyst for deracemization of alcohols. Science 382, 458–464 (2023). [DOI] [PubMed] [Google Scholar]
  • 31.Thach DQ, Knowles RR, Light-Driven C(sp3)─C(sp3) Bond Functionalizations Enabled by the PCET Activation of Alcohol O─H Bonds. Acc. Chem. Res. 58, 2061–2071 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Xu Y, Qi X, Zheng P, Berti CC, Liu P, Dong G, Deacylative transformations of ketones via aromatization-promoted C─C bond activation. Nature 567, 373–378 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhou X, Xu Y, Dong G, Olefination via Cu-Mediated Dehydroacylation of Unstrained Ketones. J. Am. Chem. Soc. 143, 20042–20048 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Antoniotti P, Benzi P, Borocci S, Demaria C, Giordani M, Grandinetti F, Operti L, Rabezzana R, Bimolecular Homolytic Substitutions at Nitrogen: An Experimental and Theoretical Study on the Gas-Phase Reactions of Alkyl Radicals with NF3. Chem. Eur. J. 21, 15826–15834 (2015). [DOI] [PubMed] [Google Scholar]
  • 35.Kim S, Joe GH, Do JY, Novel Radical Cyclizations of Alkyl Azides. A New Route to N-Heterocycles. J. Am. Chem. Soc. 116, 5521–5522 (1994). [Google Scholar]
  • 36.Zhang Z, Zhu Q, Pyle D, Zhou X, Dong G, Methyl Ketones as Alkyl Halide Surrogates: A Deacylative Halogenation Approach for Strategic Functional Group Conversions. J. Am. Chem. Soc. 145, 21096–21103 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zhang Z, Chen K, Liu P, Dong G, Alkyl Fluoride Synthesis via Cu-Mediated Deacetylative Fluorination. J. Am. Chem. Soc. 147, 20257–20264 (2025). [DOI] [PubMed] [Google Scholar]
  • 38.Zhang Y, Huang C, Lin X, Hu Q, Hu B, Zhou Y, Zhu G, Modular Synthesis of Alkylarylazo Compounds via Iron(III)-Catalyzed Olefin Hydroamination. Org. Lett. 21, 2261–2264 (2019). [DOI] [PubMed] [Google Scholar]
  • 39.Beckwith ALJ, Wang S, Warkentin J, Intramolecular radical additions to the azo group. Fast and indiscriminate 5-exo and 6-endo cyclizations. J. Am. Chem. Soc. 109, 5289–5291 (1987). [Google Scholar]
  • 40.Ruffoni A, Mykura RC, Bietti M, Leonori D, The interplay of polar effects in controlling the selectivity of radical reactions. Nat. Synth. 1, 682–695 (2022). [Google Scholar]
  • 41.Garwood JJA, Chen AD, Nagib DA, Radical Polarity. J. Am. Chem. Soc. 146, 28034–28059 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Vitaku E, Smith DT, Njardarson JT, Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. J. Med. Chem. 57, 10257–10274 (2014). [DOI] [PubMed] [Google Scholar]
  • 43.Krappmann DN, Daniel; Dolores Schendel; Stefani Spranger, Treatment of cancer with selective inhibition of MALT1 protease by phenothiazine derivatives. WO2012-EP65072, (2013). [Google Scholar]
  • 44.Bononi G, Di Stefano M, Poli G, Ortore G, Meier P, Masetto F, Caligiuri I, Rizzolio F, Macchia M, Chicca A, Avan A, Giovannetti E, Vagaggini C, Brai A, Dreassi E, Valoti M, Minutolo F, Granchi C, Gertsch J, Tuccinardi T, Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives. J. Med. Chem. 65, 7118–7140 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kodani SD, Wan D, Wagner KM, Hwang SH, Morisseau C, Hammock BD, Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3, 14076–14086 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Guan HJ, Tao; Feng Xu; Hailong Wang, Amide derivative substituted by cycloalkyl, preparation method for amide derivative, and use in medicine. WO2020147582, (2020). [Google Scholar]
  • 47.Zhang YG, Yong; Yingshuai Liu; Zhiqiang Lin, Preparation method for deuterated compounds. WO2017045648, (2017). [Google Scholar]
  • 48.Tolchin ZA, Smith JM, 15NRORC: An Azine Labeling Protocol. J. Am. Chem. Soc. 146, 2939–2943 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lebedev O, Bredihhin A, Tšupova S, Mäeorg U, The use of polyanions of hydrazines in the synthesis of heterocycles. Tetrahedron 65, 5438–5442 (2009). [Google Scholar]
  • 50.Kim S, Joe GH, Do JY, Novel Radical Cyclizations of Alkyl Azides. A New Route to N-Heterocycles. J. Am. Chem. Soc. 116, 5521–5522 (1994). [Google Scholar]
  • 51.Amengual R, Michelet V, Genêt J-P, New studies of Rh-catalyzed addition of boronic acids under basic conditions in aqueous medium. Tetrahedron Lett. 43, 5905–5908 (2002). [Google Scholar]
  • 52.Xia Y, Ochi S, Dong G, Two-Carbon Ring Expansion of 1-Indanones via Insertion of Ethylene into Carbon─Carbon Bonds. J. Am. Chem. Soc. 141, 13038–13042 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Stork G, Brizzolara A, Landesman H, Szmuszkovicz J, Terrell R, The Enamine Alkylation and Acylation of Carbonyl Compounds. J. Am. Chem. Soc. 85, 207–222 (1963). [Google Scholar]
  • 54.Freeman PK, Tafesh AM, Clapp GE, Reactions of 4,4-diphenylcarbena-2,5-cyclohexadiene and related systems in dimethyl sulfoxide. J. Org. Chem. 54, 782–789 (1989). [Google Scholar]
  • 55.Liu X, Rong X, Liu S, Lan Y, Liu Q, Cobalt-Catalyzed Desymmetric Isomerization of Exocyclic Olefins. J. Am. Chem. Soc. 143, 20633–20639 (2021). [DOI] [PubMed] [Google Scholar]
  • 56.Talukder PR, Adam Robert; Brian Richard Blank; Ryan Keith Muir; Michael John Evans, Preparation of trioxolane derivatives for use as antimalarials. (2019). [Google Scholar]
  • 57.Matsui K, Segawa Y, Itami K, All-Benzene Carbon Nanocages: Size-Selective Synthesis, Photophysical Properties, and Crystal Structure. J. Am. Chem. Soc. 136, 16452–16458 (2014). [DOI] [PubMed] [Google Scholar]
  • 58.Dongamanti A, Aamate VK, Devulapally MG, Gundu S, Balabadra S, Manga V, Yogeeswari P, Sriram D, Balasubramanian S, Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation. Mol. Diversity 21, 999–1010 (2017). [DOI] [PubMed] [Google Scholar]
  • 59.Liu W, Zheng Y, Mao Y, Chen J, Ren X, Cheng Z, Lu Z, Desymmetrizing Isomerization of Alkene via Thiazolinyl Iminoquinoline Cobalt Catalysis. Org. Lett. 24, 1158–1163 (2022). [DOI] [PubMed] [Google Scholar]
  • 60.Zhou B, Deng S, Xu Y, Qi X, Dong G, Iridium-Catalyzed Intramolecular β–C–H Alkenylation of Ketones with Alkynes via a Hydride-Transfer Approach. J. Am. Chem. Soc. 144, 23230–23238 (2022). [DOI] [PubMed] [Google Scholar]
  • 61.O' Neill PM, Stocks PA, Sabbani S, Roberts NL, Amewu RK, Shore ER, Aljayyoussi G, Angulo-Barturén I, Belén M, Jiménez D, Bazaga SF, Martínez MS, Campo B, Sharma R, Charman SA, Ryan E, Chen G, Shackleford DM, Davies J, Nixon GL, Biagini GA, Ward SA, Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria. Bioorg. Med. Chem. 26, 2996–3005 (2018). [DOI] [PubMed] [Google Scholar]
  • 62.Palle VPB, Sarala; Nidhi Gupta; Nagarajan Muthukamal; Mandadapu Raghu Ramaiah; Manoj Kumar Khera; Lailt Kumar Baregama; Vinayak Vasantrao Kahirnar; Abhijit Ray; Dastidar Sunanda G., Preparation of isoxazolines as phosphodiesterase inhibitors. WO2006085212 A2, (2006). [Google Scholar]
  • 63.Crawley GC, Dowell RI, Edwards PN, Foster SJ, McMillan RM, Walker ERH, Waterson D, Bird TGC, Bruneau P, Girodeau JM, Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. 35, 2600–2609 (1992). [DOI] [PubMed] [Google Scholar]
  • 64.Ackermann JB, Stephan; Aurelia Conte; Daniel Hunziker; Werner Neidhart; Matthias Nettekoven; Tanja Schulz-Gasch; Stanley Wertheimer, Preparation of spiro-condensed cyclohexane derivatives as hormone sensitive lipase inhibitors useful for the treatment of diabetes. WO2011045292 A1, (2011). [Google Scholar]
  • 65.Itagaki N, Kimura M, Sugahara T, Iwabuchi Y, Organocatalytic Entry to Chiral Bicyclo[3.n.1]alkanones via Direct Asymmetric Intramolecular Aldolization. Org. Lett. 7, 4185–4188 (2005). [DOI] [PubMed] [Google Scholar]
  • 66.Salman MK, Naresh; Kirandeep Kaur; Shelly Aeron; Pakala Kumar Savithru Sarma; Sankarnarayanan Dharmarajan; Anita Mehta; Anita Chugh, Preparation of 3,6-disubstituted azabicyclo[3.1.0]hexane derivatives useful as therapeutic muscarinic receptor antagonists. IN2005DN01810 A, (2009). [Google Scholar]
  • 67.Guo J, Kuang C, Rong J, Li L, Ni C, Hu J, Rapid Deoxyfluorination of Alcohols with N-Tosyl-4-chlorobenzenesulfonimidoyl Fluoride (SulfoxFluor) at Room Temperature. Chem. Eur. J. 25, 7259–7264 (2019). [DOI] [PubMed] [Google Scholar]
  • 68.Sun SZ, Alla Yurevna; Mikhail Chafeev; Qi Jia; Zaihui Zhang; Renata Marcella Oballa, Benzenesulfonamide compounds, their preparation, and use as voltage-gated sodium channel blockers for therapy. WO2013064983 A1, (2013). [Google Scholar]
  • 69.Zhao Q, Lan T, Su S, Rao Y, Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem. Commun. 55, 369–372 (2019). [DOI] [PubMed] [Google Scholar]
  • 70.Wang DS, Sijie; Guangxin Xia; Hui Ge; Bingbin Zhang; Guoyong Huo; Lin Zhang; Chen Shi; Jiangsong Lou; Chi Zhang;, Preparation of pyrazolopyrimidine compounds as WEEl kinase inhibitors for treatment and/or prevention of cancer. CN112142747 A, (2020). [Google Scholar]
  • 71.Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K, Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med. Chem. Lett. 2, 91–96 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Dell'Erba C, Novi M, Petrillo G, Tavani C, Reactions of arylazosulfones with the conjugate bases of (tert-butoxycarbonyl)methyl and tosylmethyl isocyanide. Synthesis of substituted 1-arylimidazoles. Tetrahedron 53, 2125–2136 (1997). [Google Scholar]
  • 73.Zhang Y, Huang C, Lin X, Hu Q, Hu B, Zhou Y, Zhu G, Modular Synthesis of Alkylarylazo Compounds via Iron(III)-Catalyzed Olefin Hydroamination. Org. Lett. 21, 2261–2264 (2019). [DOI] [PubMed] [Google Scholar]
  • 74.Zhou X, Yu T, Dong G, Site-Specific and Degree-Controlled Alkyl Deuteration via Cu-Catalyzed Redox-Neutral Deacylation. J. Am. Chem. Soc. 144, 9570–9575 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Chen L, Zhang Z, Zu L, Organocatalytic Hantzsch Type Reaction Using Aryl Hydrazines, Propiolic Acid Esters and Enals: Enantioselective Synthesis of Paroxetine. Advanced Synthesis & Catalysis 362, 5385–5390 (2020). [Google Scholar]
  • 76.Bhatt T, Natte K, Transfer Hydrogenation of N- and O-Containing Heterocycles Including Pyridines with H3N–BH3 Under the Catalysis of the Homogeneous Ruthenium Precatalyst. Org. Lett. 26, 866–871 (2024). [DOI] [PubMed] [Google Scholar]
  • 77.Glennon RA, Ismaiel AE-KM, McCarthy BM, Peroutka SJ, Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur. J. Pharmacol. 168, 387–392 (1989). [DOI] [PubMed] [Google Scholar]
  • 78.Williams S, Qi L, Cox RJ, Kumar P, Xiao J, Hydrogenation of functionalised pyridines with a rhodium oxide catalyst under mild conditions. Org. Biomol. Chem. 22, 1010–1017 (2024). [DOI] [PubMed] [Google Scholar]
  • 79.Fairhurst RA, Marsilje TH, Stutz S, Boos A, Niklaus M, Chen B, Jiang S, Lu W, Furet P, McCarthy C, Stauffer F, Guagnano V, Vaupel A, Michellys P-Y, Schnell C, Jeay S, Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors. Bioorg. Med. Chem. Lett. 26, 2057–2064 (2016). [DOI] [PubMed] [Google Scholar]
  • 80.Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB, Stemp G, Thewlis KM, Vong AKK, Austin NE, Jeffrey P, Winborn KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Watson JM, Wood M, Parker SG, Ashby CR, Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor Antagonist. J. Med. Chem. 46, 4952–4964 (2003). [DOI] [PubMed] [Google Scholar]
  • 81.Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NRA, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ, Discovery and Structure–Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT2C Receptor Agonist for the Treatment of Obesity. J. Med. Chem. 51, 305–313 (2008). [DOI] [PubMed] [Google Scholar]
  • 82.Evans P, McCabe T, Morgan BS, Reau S, Double Reduction of Cyclic Aromatic Sulfonamides: A Novel Method for the Synthesis of 2- and 3-Aryl-Substituted Cyclic Amines. Org. Lett. 7, 43–46 (2005). [DOI] [PubMed] [Google Scholar]
  • 83.Sonesson C, Wikström H, Smith MW, Svensson K, Carlsson A, Waters N, Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity. Bioorg. Med. Chem. Lett. 7, 241–246 (1997). [Google Scholar]
  • 84.Gao P-F, Wang H-R, Xiao X-X, Ren W-M, Lu X-B, Zhou H, Synthesis and ring-opening polymerization of bisubstituted ε-caprolactones bearing aryl and cyano groups. Polymer 319, 128034 (2025). [Google Scholar]
  • 85.Kim D-I, Deutsch HM, Ye X, Schweri MM, Synthesis and Pharmacology of Site-Specific Cocaine Abuse Treatment Agents: Restricted Rotation Analogues of Methylphenidate. J. Med. Chem. 50, 2718–2731 (2007). [DOI] [PubMed] [Google Scholar]
  • 86.Klumpp DA, Garza M, Jones A, Mendoza S, Synthesis of Aryl-Substituted Piperidines by Superacid Activation of Piperidones. J. Org. Chem. 64, 6702–6705 (1999). [DOI] [PubMed] [Google Scholar]
  • 87.Murali Dhar TG, Nagarathnam D, Marzabadi MR, Lagu B, Wong WC, Chiu G, Tyagarajan S, Miao SW, Zhang F, Sun W, Tian D, Shen Q, Zhang J, Wetzel JM, Forray C, Chang RSL, Broten TP, Schorn TW, Chen TB, O'Malley S, Ransom R, Schneck K, Bendesky R, Harrell CM, Vyas KP, Zhang K, Gilbert J, Pettibone DJ, Patane MA, Bock MG, Freidinger RM, Gluchowski C, Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 2. Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine Moiety. J. Med. Chem. 42, 4778–4793 (1999). [DOI] [PubMed] [Google Scholar]
  • 88.Orjales A, Mosquera R, Toledo A, Pumar MC, García N, Cortizo L, Labeaga L, Innerárity A, Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters. J. Med. Chem. 46, 5512–5532 (2003). [DOI] [PubMed] [Google Scholar]
  • 89.Granchi C, Lapillo M, Glasmacher S, Bononi G, Licari C, Poli G, el Boustani M, Caligiuri I, Rizzolio F, Gertsch J, Macchia M, Minutolo F, Tuccinardi T, Chicca A, Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor. J. Med. Chem. 62, 1932–1958 (2019). [DOI] [PubMed] [Google Scholar]
  • 90.Ismaiel AM, Arruda K, Teitler M, Glennon RA, Ketanserin Analogs: The Effect of Structural Modification on 5-HT2 Serotonin Receptor Binding. J. Med. Chem. 38, 1196–1202 (1995). [DOI] [PubMed] [Google Scholar]
  • 91.Recanatini M, Tumiatti V, Budriesi R, Chiarini A, Sabatino P, Bolognesi ML, Melchiorre C, Synthesis, muscarinic blocking activity and molecular modeling studies of 4-DAMP-related compounds. Bioorg. Med. Chem. 3, 267–277 (1995). [DOI] [PubMed] [Google Scholar]
  • 92.She X, Pegoli A, Mayr J, Hübner H, Bernhardt G, Gmeiner P, Keller M, Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity. ACS Omega 2, 6741–6754 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Hirota CL, McKay DM, Cholinergic regulation of epithelial ion transport in the mammalian intestine. Br. J. Pharmacol. 149, 463–479 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Liu X-G, Zhou C-J, Lin E, Han X-L, Zhang S-S, Li Q, Wang H, Decarboxylative Negishi Coupling of Redox-Active Aliphatic Esters by Cobalt Catalysis. Angew. Chem. Int. Ed. 57, 13096–13100 (2018). [DOI] [PubMed] [Google Scholar]
  • 95.Loozen HJJ, Brands FTL, An efficient synthesis of 3-arylpiperidines. Recl. Trav. Chim. Pays-Bas 100, 333–336 (1981). [Google Scholar]
  • 96.Sonesson C, Waters N, Svensson K, Carlsson A, Smith MW, Piercey MF, Meier E, Wikstroem H, Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J. Med. Chem. 36, 3188–3196 (1993). [DOI] [PubMed] [Google Scholar]
  • 97.Fyfe TJ, Kellam B, Sykes DA, Capuano B, Scammells PJ, Lane JR, Charlton SJ, Mistry SN, Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor. J. Med. Chem. 62, 9488–9520 (2019). [DOI] [PubMed] [Google Scholar]
  • 98.Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC, T. C. M. Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, BVNBS S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN, Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science 382, eabo7201 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Varasi M, Thaler F, Abate A, Bigogno C, Boggio R, Carenzi G, Cataudella T, Dal Zuffo R, Fulco MC, Rozio MG, Mai A, Dondio G, Minucci S, Mercurio C, Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. J. Med. Chem. 54, 3051–3064 (2011). [DOI] [PubMed] [Google Scholar]
  • 100.Yang L, Morriello G, Prendergast K, Cheng K, Jacks T, Chan WWS, Schleim KD, Smith RG, Patchett AA, Potent 3-spiropiperidine growth hormone secretagogues. Bioorg. Med. Chem. Lett. 8, 107–112 (1998). [DOI] [PubMed] [Google Scholar]
  • 101.Ghandi M, Sherafat F, Sadeghzadeh M, Alirezapour B, One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives. Bioorg. Med. Chem. Lett. 26, 2676–2679 (2016). [DOI] [PubMed] [Google Scholar]
  • 102.Chen M-H, Pollard PP, Patchett AA, Cheng K, Wei L, Chan WWS, Butler B, Jacks TM, Smith RG, Synthesis and biological activities of spiroheterocyclic growth hormone secretagogues. Bioorg. Med. Chem. Lett. 9, 1261–1266 (1999). [DOI] [PubMed] [Google Scholar]
  • 103.Moltzen EK, Perregaard J, Meier E, .sigma. Ligands with Subnanomolar Affinity and Preference for the .sigma.2 Binding Site. 2. Spiro-Joined Benzofuran, Isobenzofuran, and Benzopyran Piperidines. J. Med. Chem. 38, 2009–2017 (1995). [DOI] [PubMed] [Google Scholar]
  • 104.Stokbroekx R. A. V. d. A., Luyckx Marcel J. M., Grauwels Marcel G. M., Gilbert AJ, Pyridazine derivatives as antivirals. EP320032 A1, (1989). [Google Scholar]
  • 105.Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KGW, Tucker SPT, Reece PAR, In Vitro Activity of Expanded-Spectrum Pyridazinyl Oxime Ethers Related to Pirodavir: Novel Capsid-Binding Inhibitors with Potent Antipicornavirus Activity. Antimicrob. Agents Chemother. 48, 1766–1772 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Scheithauer S, Synthesis of some metabolites of the bladder spasmolytic propiverine hydrochloride (Mictonorm). Pharmazie 43, 86–90 (1988). [PubMed] [Google Scholar]
  • 107.McKeage K, Propiverine. Clin. Drug Invest. 33, 71–91 (2013). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Materials

RESOURCES